Sugi Predict

Sugi Predict / Compounds / SCHEMBL7208733

SCHEMBL7208733

SCHEMBL7208733

O=C(Nc1ccc(Cl)cc1)c1cc(Br)ccc1NS(=O)(=O)c1ccccc1F

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC10A6 Q3KNW5 2/20 0.71
▸ SLC10A2 Q12908 1/20 0.71
▸ SLC10A1 Q14973 1/20 0.71
▸ KMT2A Q03164 5/20 0.57
▸ LMNA P02545 3/20 0.57
▸ ALDH1A1 P00352 2/20 0.57
▸ GAA P10253 2/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ NPC1 O15118 1/20 0.57
▸ RAB9A P51151 1/20 0.57
▸ MEN1 O00255 4/20 0.53
▸ METAP2 P50579 1/20 0.51
▸ GPR27 Q9NS67 5/20 0.51
▸ MAPT P10636 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ TP53 P04637 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7117455 0.93 SLC10A2 (0.60) SLC10A6SLC10A2SLC10A1KMT2ALMNA
SCHEMBL7214441 0.91 GPR27 (0.57) SLC10A6SLC10A2SLC10A1KMT2ALMNA
SCHEMBL7128109 0.87 MEN1 (0.64) SLC10A6SLC10A2SLC10A1KMT2ALMNA
SCHEMBL6756862 0.83 SLC10A6 (1.00) SLC10A6SLC10A2SLC10A1KMT2ALMNA
SCHEMBL7128140 0.83 SLC10A6 (0.61) SLC10A6SLC10A2SLC10A1KMT2ALMNA
SCHEMBL7126120 0.82 SLC10A6 (0.98) SLC10A6SLC10A2SLC10A1KMT2ALMNA
SCHEMBL7124358 0.81 SLC10A6 (0.59) SLC10A6SLC10A2SLC10A1KMT2ALMNA
SCHEMBL7128469 0.80 SLC10A2 (0.60) SLC10A6SLC10A2SLC10A1KMT2ALMNA
SCHEMBL7209357 0.80 SLC10A6 (0.76) SLC10A6SLC10A2SLC10A1KMT2ALMNA
SCHEMBL7213174 0.79 SLC10A6 (0.61) SLC10A6SLC10A2SLC10A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1187531-A4 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2003-05-28 — — EP claimed
US-6458845-B1 METHOD OF ANTAGONIZING A MACROPHAGE SCAVENGER RECEPTOR COMPRISING ADMINISTERING TO A SUBJECT IN NEED OF TREATMENT AN EFFECTIVE AMOUNT OF AN N-PHENYL-2-(3-TRIFLUOROMETHYLPHENYLSULFONAMIDO)BENZAMIDE, A SMITHKLINE BEECHAM CORPORATION 2002-10-01 — — US claimed
CN-1358062-A Macrophage scavenger receptor antagonists SMITHKLINE BEECHAM CORP (US) 2002-07-10 — — CN claimed
EP-1187531-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-03-20 — — EP claimed
WO-2001098264-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-12-27 — — WO claimed
WO-2000078145-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-12-28 — — WO claimed
EP-1187531-A4 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2003-05-28 — — EP disclosed
US-6458845-B1 METHOD OF ANTAGONIZING A MACROPHAGE SCAVENGER RECEPTOR COMPRISING ADMINISTERING TO A SUBJECT IN NEED OF TREATMENT AN EFFECTIVE AMOUNT OF AN N-PHENYL-2-(3-TRIFLUOROMETHYLPHENYLSULFONAMIDO)BENZAMIDE, A SMITHKLINE BEECHAM CORPORATION 2002-10-01 — — US disclosed
CN-1358062-A Macrophage scavenger receptor antagonists SMITHKLINE BEECHAM CORP (US) 2002-07-10 — — CN disclosed
EP-1187531-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-03-20 — — EP disclosed
WO-2001098264-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-12-27 — — WO disclosed
WO-2000078145-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-12-28 — — WO disclosed